Category Research

Reflow Medical Launches Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters in the U.S.

Reflow Medical Unveils U.S. Launch of Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters Reflow Medical, Inc. has announced the U.S. commercial launch of its next-generation Cora Flex® and Cora Force® Torqueable Microcatheters, marking a significant expansion of its coronary…

Read MoreReflow Medical Launches Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters in the U.S.

Study Links Muscle Composition to Elevated Chronic Kidney Disease Risk and Higher Mortality

New AMRA Study Links Muscle Composition to Elevated Risk of Chronic Kidney Disease and Increased Mortality AMRA Medical has released new research shedding light on an important and previously underappreciated factor influencing outcomes in patients with Chronic Kidney Disease. The…

Read MoreStudy Links Muscle Composition to Elevated Chronic Kidney Disease Risk and Higher Mortality

Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting

Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for neurological and metabolic disorders, has announced promising results from a…

Read MoreKallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting

Segal Trials Positioned to Support Next Wave of Clinical Development as Federal Fast-Tracking Boosts Psychedelic Therapies

As Federal Fast-Tracking of Psychedelic Treatments Gains Momentum, Segal Trials Is Poised to Advance the Next Stage of Clinical Development The recent federal directive encouraging the U.S. Food and Drug Administration to accelerate the review of psychedelic-based therapies signals a…

Read MoreSegal Trials Positioned to Support Next Wave of Clinical Development as Federal Fast-Tracking Boosts Psychedelic Therapies

From IVF Innovation to Skin Longevity: AV Laboratories Turns Biotechnology into Breakthrough Skincare

AV Laboratories Transforms IVF Science into Breakthrough Skin Longevity Innovations AV Laboratories is positioning itself at the forefront of a new era in skincare by bringing together decades of advanced biotechnology research and translating it into clinically inspired formulations designed…

Read MoreFrom IVF Innovation to Skin Longevity: AV Laboratories Turns Biotechnology into Breakthrough Skincare

Agenus to Present Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Agenus to Showcase Initial Phase 2 Botensilimab Results in Advanced Cutaneous Melanoma at ASCO 2026 Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing next-generation cancer immunotherapies, announced today that four scientific abstracts featuring its lead checkpoint inhibitor…

Read MoreAgenus to Present Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Speak Foundation Launches National LGMD Centers of Excellence to Advance Trials and Therapies

Speak Foundation Introduces Patient-Led National LGMD Centers of Excellence to Drive Clinical Trials and Innovative Treatments Speak Foundation has announced the launch of a major new initiative aimed at transforming care delivery and accelerating therapeutic development for patients living with…

Read MoreSpeak Foundation Launches National LGMD Centers of Excellence to Advance Trials and Therapies

RareCyte Advances Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Key Leadership Appointment

RareCyte Broadens Clinical-Scale Spatial Proteomics Offering with New Orion Systems and Leadership Addition RareCyte has announced a major expansion of its spatial proteomics capabilities, marking a strategic step forward in its mission to advance biomarker-driven research and precision medicine. The…

Read MoreRareCyte Advances Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Key Leadership Appointment

Synthetic Design Lab Debuts First Logic-Gated ADC at AACR 2026, Delivering ≥10X Enhanced Targeted Cancer Cell Killing

Synthetic Design Lab reveals first logic-gated ADC at AACR 2026 with ≥10x enhanced targeted cancer cell killing Synthetic Design Lab, an emerging innovator in the field of antibody-drug conjugates (ADCs) and advanced protein engineering, has unveiled compelling preclinical findings that…

Read MoreSynthetic Design Lab Debuts First Logic-Gated ADC at AACR 2026, Delivering ≥10X Enhanced Targeted Cancer Cell Killing

Zai Lab Highlights Zoci’s Strong Brain Tumor Responses in SCLC and Neuroendocrine Cancers

Zai Lab reports strong, rapid brain metastasis responses with Zocilurtatug Pelitecan in SCLC and other neuroendocrine cancers Zai Lab Limited has unveiled compelling new clinical and preclinical data highlighting the potential of its oncology pipeline, led by zocilurtatug pelitecan (zoci,…

Read MoreZai Lab Highlights Zoci’s Strong Brain Tumor Responses in SCLC and Neuroendocrine Cancers